Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125162 | 1.00 | TSHR (0.39) | TSHRALDH1A1CYP3A4SLC15A1ANPEP | |
| SCHEMBL11806787 | 1.00 | TSHR (0.39) | TSHRALDH1A1CYP3A4SLC15A1ANPEP | |
| SCHEMBL11802674 | 0.94 | ACE2 (0.40) | TSHRALDH1A1ANPEPERAP2CNR1 | |
| SCHEMBL11799490 | 0.92 | ACE2 (0.43) | TSHRALDH1A1CYP3A4ANPEPERAP2 | |
| SCHEMBL7962706 | 0.87 | TSHR (0.54) | TSHRANPEP | |
| SCHEMBL12285467 | 0.85 | TSHR (0.43) | TSHRALDH1A1CYP3A4SLC15A1ANPEP | |
| SCHEMBL17919006 | 0.85 | TSHR (0.43) | TSHRALDH1A1CYP3A4SLC15A1ANPEP | |
| SCHEMBL172661 | 0.85 | TSHR (0.46) | TSHRALDH1A1CYP3A4SLC15A1ANPEP | |
| SCHEMBL6119034 | 0.83 | ALDH1A1 (0.40) | TSHRALDH1A1CYP3A4SLC15A1CNR1 | |
| SCHEMBL20036791 | 0.83 | TSHR (0.52) | TSHRALDH1A1CYP3A4ANPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TSHR 1106/4885ALDH1A1 3811/4885CYP3A4 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.